Developing CRISPR medicines that edit genes inside the body, still in clinical trials.
$11.42close as of 2026-10-16
-54.2% over 1Y · 70.9 points behind the S&P 500
NTLAS&P 500 (SPY), rebased to NTLA's first close
“Can Intellia turn lonvo-z’s attack reductions into an approved launch while managing nex-z’s liver safety concerns?”
Editorial note · updated 2026-10-08
The TenQ Radar
Intellia Therapeutics in 36 checks
Intellia Therapeutics on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 7 of 36 checks passed.
The Intellia Therapeutics story
What drives Intellia Therapeutics, what its price assumes and what could change the story, written from its own filings.
Lonvo-z enters review. On September 8, 2026, the FDA accepted lonvo-z’s biologics license application with Priority Review, following an 87% reduction in attacks versus placebo in Phase 3 HAELO.
Nex-z enrollment resumes. Intellia reported resumed Phase 3 enrollment in the quarter to June 2026 and introduced HLA genotyping after linking a specific allele to the highest observed liver enzyme elevations.
Financing supports launch preparations. Following a $195 million public offering in April 2026, Intellia secured a $400 million senior secured loan facility with OrbiMed in September 2026, with $75 million funded at closing.
Q2 '26 · quarter to 30 June 2026 · reported 6 August 2026 · Earnings release ↗
Revenue$8M-46%vs 2025-49%vs Q1
Earnings-$107M-$5Mvs 2025-$10Mvs Q1
What the release says
Highlights
Intellia reported positive Phase 3 HAELO clinical trial results for lonvo-z in hereditary angioedema, with an 87% reduction in attacks versus placebo and all key secondary endpoints met with statistical significance.
Enrollment was successfully reinitiated in nex-z Phase 3 clinical trials, and MAGNITUDE-2 enrollment in ATTRv-PN is expected to be completed in the second half of 2026.
A comprehensive genomic analysis identified a specific HLA allele associated with higher liver transaminase elevations in nex-z trials, and HLA genotyping will now be provided to investigators and patients in ongoing studies.
The company ended the quarter with $628.4 million in cash, cash equivalents and marketable securities, following a $195 million capital raise, and expects to fund operations at least into 2028.
What management expects
Intellia expects the U.S. Food and Drug Administration (FDA) to accept its submission of a biologics license application (BLA) for lonvo-z in the second half of 2026.
If approved, Intellia plans to launch lonvo-z commercially in the first half of 2027.
The company remains on track to complete patient enrollment in the MAGNITUDE-2 Phase 3 trial of nex-z in the second half of 2026.
Key risks
New Intellia faces significant competition for its lonvo-z and nex-z programs from companies developing genome editing, gene therapy, and traditional therapies for HAE and ATTR amyloidosis, which could impact its market share and commercial prospects.
New Recent and potential future U.S. government drug pricing proposals, such as GLOBE, GUARD, and GENEROUS, could materially impact Intellia's revenue if adopted.
The therapeutic utility of in vivo CRISPR-based genome editing technologies is largely unproven, and if Intellia is unable to develop viable product candidates or achieve regulatory approval, it may never achieve profitability.
Clinical development is lengthy, expensive, and uncertain, and delays or failures in clinical trials for lonvo-z, nex-z, or other candidates could prevent or delay regulatory approval and commercialization.
Adverse events, inconclusive results, or additional safety concerns in Intellia's or others' clinical trials, such as the previously reported Grade 4 liver transaminase elevations and patient death in the MAGNITUDE trial, may impede regulatory approval or market acceptance of product candidates.
Intellia's commercial success depends on avoiding infringement of third-party patents, and ongoing or future intellectual property disputes could result in significant costs, delays, or inability to commercialize products.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when Intellia Therapeutics reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●1/6
Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.
-no history
26.9xown 9-year median 34.2x
-21.8%cash earned per $ of price
-whole-business multiple
Valuation history
Is NTLA's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2026
-
26.8922
2.199
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 26.9x sales, the market is paying 21% less than NTLA's own 9-year median of 34.2x. Pessimism is priced in - the question is whether it is deserved.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Free cash flow yield
What is NTLA's free cash flow yield at today's price?
Period
FCF yield
2017
-0.1209
2018
-0.065
2019
-0.1543
2020
-0.0434
2021
-0.0316
2022
-0.0736
2023
-0.1249
2024
-0.1595
2025
-0.328
2026
-0.2179
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys -21.8% of annual free cash flow, more than its 9-year median of -12.1% - the cash is cheaper than usual.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●1/6
Growth is weak or inconsistent. The trend, not the story, is the problem.
+12.6%vs the year before
+9.1%compound annual
-net income growth
-compound annual
Revenue history
Is NTLA's revenue growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q1 2017
6.2M
Q2 2017
5.9M
Q3 2017
7.3M
Q4 2017
6.7M
Q1 2018
7.5M
Q2 2018
7.7M
Q3 2018
7.4M
Q4 2018
7.9M
Q1 2019
10.4M
Q2 2019
11.1M
Q3 2019
10.6M
Q4 2019
10.9M
Q1 2020
12.9M
Q2 2020
16.3M
Q3 2020
22.2M
Q4 2020
6.6M
Q1 2021
6.4M
Q2 2021
6.5M
Q3 2021
7.2M
Q4 2021
12.9M
Q1 2022
11.3M
Q2 2022
14.0M
Q3 2022
13.3M
Q4 2022
13.6M
Q1 2023
12.6M
Q2 2023
13.6M
Q3 2023
12.0M
Q1 2024
28.9M
Q2 2024
7.0M
Q3 2024
9.1M
Q4 2024
12.9M
Q1 2025
16.6M
Q2 2025
14.2M
Q3 2025
13.8M
Q4 2025
23.0M
Q1 2026
15.0M
Q2 2026
7.7M
2016
16.5M
2017
26.1M
2018
30.4M
2019
43.1M
2020
58.0M
2021
33.1M
2022
52.1M
2023
36.3M
2024
57.9M
2025
67.7M
→Revenue reached $68M in 2025, compounding +9% a year since 2022 and the pace is picking up. The trailing twelve months are already running at $60M, behind the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Profit history
Is NTLA's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q1 2015
-1.1M
Q2 2015
-3.0M
Q3 2015
-3.0M
Q4 2015
-5.2M
Q1 2016
-6.7M
Q2 2016
-6.9M
Q3 2016
-7.5M
Q4 2016
-10.6M
Q1 2017
-12.6M
Q2 2017
-15.6M
Q3 2017
-15.4M
Q4 2017
-24.0M
Q1 2018
-21.4M
Q2 2018
-22.2M
Q3 2018
-22.7M
Q4 2018
-19.1M
Q1 2019
-21.9M
Q2 2019
-25.7M
Q3 2019
-23.6M
Q4 2019
-28.3M
Q1 2020
-31.8M
Q2 2020
-32.4M
Q3 2020
-27.8M
Q4 2020
-42.2M
Q1 2021
-46.2M
Q2 2021
-68.8M
Q3 2021
-71.6M
Q4 2021
-81.2M
Q1 2022
-146.9M
Q2 2022
-100.7M
Q3 2022
-113.2M
Q4 2022
-113.4M
Q1 2023
-103.1M
Q2 2023
-123.7M
Q3 2023
-122.2M
Q4 2023
-132.2M
Q1 2024
-107.4M
Q2 2024
-147.0M
Q3 2024
-135.7M
Q4 2024
-128.9M
Q1 2025
-114.3M
Q2 2025
-101.3M
Q3 2025
-101.3M
Q4 2025
-95.8M
Q1 2026
-96.2M
Q2 2026
-106.6M
2015
-12.4M
2016
-31.6M
2017
-67.5M
2018
-85.3M
2019
-99.5M
2020
-134.2M
2021
-267.9M
2022
-474.2M
2023
-481.2M
2024
-519.0M
2025
-412.7M
→The company lost $413M in 2025, less than the $519M it lost the year before. The losses are narrowing, but it is still burning shareholder money.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are NTLA's revenue and earnings growing?
Year
Revenue growth
Earnings growth
2,017
0.5849
-
2,018
0.1653
-
2,019
0.4163
-
2,020
0.3455
-
2,021
-0.4301
-
2,022
0.5769
-
2,023
-0.304
-
2,024
0.5955
-
2,025
0.1692
-
2026
0.1258
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue grew 13% over the twelve months to 2026-06-30, against an average of +12% a year over 2021-2025.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are NTLA's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,017
0.7269
-2.0978
2,018
0.7061
-1.5687
2,019
0.9137
-2.3326
2,020
1.0358
-0.9555
2,021
0.4662
-3.3541
2,022
0.6771
-4.5061
2,023
0.4086
-4.5969
2,024
0.5855
-3.5879
2,025
0.6244
-3.6527
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $0.62 in 2025, compounding -3% a year against +9% for NTLA as a whole. Dilution absorbed about 11.8 points of that growth. The trailing twelve months are running at $0.55 a share. Free cash flow per share stands at $-3.65.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
100.0%kept after direct costs
-711.7%kept after running costs
-profit on shareholders' money
-54.4%against a 10% cost of capital
-operating cash ÷ net income
Margins
What profit margin does NTLA keep on each sale?
Year
Gross
Operating
Net
2,016
-
-1.9515
-1.9197
2,017
-
-2.6632
-2.5862
2,018
1
-2.9858
-2.8042
2,019
1
-2.4678
-2.3092
2,020
1
-2.3551
-2.3146
2,021
1
-8.1037
-8.1049
2,022
-
-8.7904
-9.0978
2,023
-
-14.2051
-13.2651
2,024
-
-9.231
-8.9677
2,025
-
-6.5167
-6.0985
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating margin widened 227 points to -652% since 2022. The bottom line is still negative: costs below the operating line eat what is left.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does NTLA's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,015
-1.8M
-12.4M
2,016
36.1M
-31.6M
2,017
-65.3M
-67.5M
2,018
-61.3M
-85.3M
2,019
-103.2M
-99.5M
2,020
-49.9M
-134.2M
2,021
-225.0M
-267.9M
2,022
-333.3M
-474.2M
2,023
-394.1M
-481.2M
2,024
-348.9M
-519.0M
2,025
-394.7M
-412.7M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated -$395M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does NTLA earn?
Year
ROE
ROA
ROCE
2,017
-0.2646
-0.1795
-0.2017
2,018
-0.295
-0.2457
-0.2962
2,019
-0.3634
-0.2978
-0.3562
2,020
-0.3369
-0.1985
-0.2232
2,021
-0.3418
-0.207
-0.2292
2,022
-0.4167
-0.3119
-0.3288
2,023
-0.421
-0.3699
-0.4346
2,024
-0.54
-0.4358
-0.4946
2,025
-0.5348
-0.4901
-0.5974
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of -53% and ROCE of -54% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Income waterfall
Where does NTLA's revenue go, from sales to net profit?
Step
Amount ($)
Revenue, last 12m
59.5M
Gross profit
59.5M
Operating income
-423.5M
Net income
-400.0M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Of $60M over the twelve months to 2026-06-30 sales, nothing reaches the bottom line - the journey from revenue to profit ends $400M underwater.
What this measures
One year of revenue, with each major cost taken out in the order the income statement takes it, ending at net profit.
What good looks like. No single step swallowing a surprising share, and a bottom line that survives all of them.
If it rises or falls. The largest step is where the business really spends its money, and it is the one to watch year to year: a step that grows faster than revenue is what margin compression looks like before it reaches the margin chart.
Cash conversion
How much of each sale does NTLA turn into free cash flow?
Period
FCF margin
2016
1.8171
2017
-2.8857
2018
-2.2217
2019
-2.5528
2020
-0.9225
2021
-7.1941
2022
-6.6546
2023
-11.2494
2024
-6.1278
2025
-5.8498
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does NTLA spend on capex, R&D and stock pay?
Year
Capex % of rev
R&D % of rev
Stock comp % of rev
2,016
0.3741
1.9322
0.4075
2,017
0.3864
2.5902
0.5867
2,018
0.2089
2.9281
0.5601
2,019
0.1576
2.5152
0.3501
2,020
0.0618
2.5935
0.3432
2,021
0.3859
6.9527
1.4222
2,022
0.2601
8.0578
1.7536
2,023
0.3855
11.9936
3.6954
2,024
0.0998
8.0569
2.6655
2,025
0.0167
5.7463
1.1854
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is research and development, at 575% of revenue (stock compensation 119%, capital spending 2%). That share has fallen since 2022, so the cost of competing is easing.
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
Return on capital employed
Is NTLA's return on capital above what its capital costs?
Period
Return on capital employed
2015
-0.1877
2016
-0.1199
2017
-0.2017
2018
-0.2962
2019
-0.3562
2020
-0.2232
2021
-0.2292
2022
-0.3288
2023
-0.4346
2024
-0.4946
2025
-0.5974
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→NTLA's return on capital is negative at -59.7% in 2025. The capital in the business is not yet earning anything back.
What this measures
The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.
What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.
If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow -$347M on a net loss of $400M
IV
Financial health
●●●●●●4/6
Financially sound overall, with one or two things worth watching.
0.00xborrowed vs owned
6.6xnear-term bills coverage
-earnings ÷ interest bill
$438Mcash plus short-term investments
Debt & cash
How much debt does NTLA carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,014
0
9.8M
2,015
0
75.8M
2,016
0
273.1M
2,017
0
340.7M
2,018
0
314.1M
2,019
0
279.7M
2,020
0
597.4M
2,021
0
748.7M
2,022
0
1.19B
2,023
0
912.2M
2,024
0
601.5M
2,025
0
449.9M
2,026
0
437.8M
◌ each quarterly point is the balance sheet at that quarter end
→The company holds $438M in cash against $0.00 of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do NTLA's current assets cover the bills due within a year?
Period
Current ratio
2015
7.2582
2016
9.1541
2017
11.3151
2018
8.0099
2019
8.124
2020
9.595
2021
6.1137
2022
9.6148
2023
8.6655
2024
5.7723
2025
5.0798
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is comfortable: 6.6x of current assets for every dollar due within the year. That is much the same than in 2015.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Cash conversion
How much of NTLA's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2016
2.1912
2017
-2.4994
2018
-2.0128
2019
-2.3952
2020
-0.8606
2021
-6.8082
2022
-6.3945
2023
-10.8638
2024
-6.028
2025
-5.8332
◌ each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→NTLA's operations consumed cash rather than produced it over the last twelve months. Down from 219.1% in 2016.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is NTLA's shareholder equity (book value) growing?
Period
Equity ($)
2014
7.6M
2015
-21.2M
2016
209.8M
2017
300.6M
2018
277.9M
2019
269.9M
2020
527.1M
2021
1.04B
2022
1.24B
2023
1.05B
2024
872.0M
2025
671.4M
2026
727.7M
→The company's own capital shrank from $1.1B in 2023 to $728M (-31%). Buybacks or losses are drawing the buffer down - the distinction matters.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
NTLA returns nothing to shareholders yet, and the share count keeps rising. Every dollar stays in the business.
-bought back, TTM, over market value
-at the current rate
-dividends plus buybacks
$68Mlast 12m, dilutes the buybacks
+224.2%since 2017 (split-adjusted)
Share count change (split-adjusted)
Is NTLA's share count rising or falling?
Year
Share-count change
2,018
0.1997
2,019
0.0944
2,020
0.1869
2,021
0.2663
2,022
0.0857
2,023
0.1533
2,024
0.1135
2,025
0.0964
→The share count grew 9.6% in 2025, averaging 12.1% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dilution against what it bought
Has NTLA's revenue per share grown faster than its share count?
Change since 2017. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2017
Revenue per share, change since 2017
2,017
0
0
2,018
0.1997
-0.0287
2,019
0.313
0.257
2,020
0.5583
0.4249
2,021
0.9733
-0.3586
2,022
1.1424
-0.0685
2,023
1.4708
-0.4379
2,024
1.7514
-0.1946
2,025
2.0166
-0.141
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→NTLA issued 202% more shares from 2017 to 2025 and revenue per share still fell 14%. On this measure the new shares have not paid for themselves.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→NTLA is in a downtrend: the price is below the cloud where recent trading settled and that cloud is still falling. Both shorter readings point down as well, so nothing here disagrees with the downtrend.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are NTLA's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2023-11
0
0
2023-12
0
0
2024-01
0
1.5M
2024-02
0
0
2024-03
0
95,737
2024-04
0
0
2024-05
0
0
2024-06
0
37,625
2024-07
0
0
2024-08
0
0
2024-09
0
0
2024-10
0
38,248
2024-11
0
0
2024-12
0
0
2025-01
0
827,228
2025-02
0
0
2025-03
0
29,226
2025-04
0
2,253
2025-05
0
0
2025-06
0
14,789
2025-07
0
143,801
2025-08
1.0M
0
2025-09
0
0
2025-10
0
33,057
2025-11
0
0
2025-12
0
836,384
2026-01
1.4M
772,139
2026-02
0
0
2026-03
0
25,052
2026-04
0
0
2026-05
0
0
2026-06
0
0
2026-07
0
219,751
2026-08
0
286,819
2026-09
0
0
2026-10
0
23,170
→Since November 2023, insiders bought $2M and sold $5M on the open market, a net sale of $2M. A further 57 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-10-02
Michael P Dube
VP, Chief Accounting Officer
SELL
1,864
$12.43
$23,170
2026-08-21
John M Leonard
President and CEO
SELL
2,785
$13.00
$36,205
2026-08-20
John M Leonard
President and CEO
SELL
19,890
$12.60
$250,614
2026-07-22
Edward J Dulac III
EVP, Chief Financial Officer
SELL
8,111
$11.25
$91,249
2026-07-02
Edward J Dulac III
EVP, Chief Financial Officer
SELL
4,677
$18.00
$84,186
2026-07-01
Michael P Dube
VP, Chief Accounting Officer
SELL
2,641
$16.78
$44,316
2026-03-02
James Basta
EVP, General Counsel
SELL
1,211
$13.78
$16,688
2026-03-02
Eliana Clark
EVP, Chief Technical Officer
SELL
607
$13.78
$8,364
2026-01-05
John M Leonard
President and CEO
SELL
34,146
$9.21
$314,485
2026-01-05
Birgit C Schultes
EVP, Chief Scientific Officer
SELL
8,508
$9.21
$78,359
2026-01-05
James Basta
EVP, General Counsel
SELL
10,397
$9.21
$95,756
2026-01-05
Fred E Cohen
Director
BUY
150,000
$9.35
$1.4M
2026-01-05
David Lebwohl
EVP, Chief Medical Officer
SELL
11,903
$9.21
$109,627
2026-01-05
Eliana Clark
EVP, Chief Technical Officer
SELL
9,515
$9.21
$87,633
2026-01-05
Edward J Dulac III
EVP, Chief Financial Officer
SELL
6,379
$9.21
$58,751
2026-01-05
Michael P Dube
VP, Chief Accounting Officer
SELL
2,989
$9.21
$27,529
2025-12-12
John M Leonard
President and CEO
exercise
8,557
$6.83
$58,444
2025-12-11
John M Leonard
President and CEO
exercise
49,959
$6.83
$341,220
2025-12-11
John M Leonard
President and CEO
SELL
49,959
$9.49
$474,111
2025-12-11
John M Leonard
President and CEO
SELL
32,832
$9.47
$310,919
2025-12-11
John M Leonard
President and CEO
SELL
5,355
$9.59
$51,354
2025-10-01
Birgit C Schultes
EVP, Chief Scientific Officer
SELL
31
$17.38
$539
2025-10-01
Michael P Dube
VP, Chief Accounting Officer
SELL
1,871
$17.38
$32,518
2025-08-20
William J Chase
Director
BUY
100,000
$10.03
$1M
2025-07-23
Edward J Dulac III
EVP, Chief Financial Officer
SELL
7,462
$14.02
$104,617
2025-07-02
Michael P Dube
VP, Chief Accounting Officer
SELL
2,503
$9.95
$24,905
2025-07-01
Eliana Clark
EVP, Chief Technical Officer
Plan purchase
1,022
$9.82
$10,036
2025-07-01
Jesse Goodman
Director
SELL
1,547
$9.23
$14,279
2025-06-30
Jesse Goodman
Director
SELL
1,547
$9.56
$14,789
2025-04-29
Muna Bhanji
Director
SELL
265
$8.50
$2,253
2025-03-04
Eliana Clark
EVP, Chief Technical Officer
SELL
679
$8.99
$6,104
2025-03-04
James Basta
EVP, General Counsel
SELL
2,572
$8.99
$23,122
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
102.8%on Form 13F, 30 June 2026
1.9%officers, directors, founders
56.8%together
1of the 18 TenQ follows
Top holders
Who owns Intellia Therapeutics stock?
Fund managers filing Form 13F held 102.8% of the company's shares on 30 June 2026. The largest holder is ARK Investment Management LLC, with 12.0%. Insiders hold 1.9%.
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Super investors
Which super investors own Intellia Therapeutics stock?
Cathie Wood's ARK Investment Management holds Intellia Therapeutics, 1.9% of its portfolio, as of 30 June 2026. It is the only one of the 18 super investors TenQ follows that holds it.
Source: each firm's Form 13F for the quarter to 30 June 2026, and its Form 4 and Schedules 13D and 13G since. A weight is the holding's share of the firm's 13F portfolio. All super investors
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.